Cargando…
The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has b...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469945/ https://www.ncbi.nlm.nih.gov/pubmed/23087503 http://dx.doi.org/10.4103/0253-7613.99301 |
_version_ | 1782246162951045120 |
---|---|
author | Zabihollahi, Rezvan Namazi, Rahele Aghasadeghi, Mohammad Reze Esfahani, Azar Farhang Sadat, Seyed Mehdi Modarressi, Mohammad Hossein |
author_facet | Zabihollahi, Rezvan Namazi, Rahele Aghasadeghi, Mohammad Reze Esfahani, Azar Farhang Sadat, Seyed Mehdi Modarressi, Mohammad Hossein |
author_sort | Zabihollahi, Rezvan |
collection | PubMed |
description | OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has been proved in previous clinical trials. Here the in vitro inhibitory effect of IMOD against HIV-1, Herpes simplex virus (HSV) and murine leukemia viruses (MLV) was evaluated. MATERIALS AND METHODS: HIV single cycle replication and HSV plaque reduction assays were used to evaluate the anti-viral effect. The level of HIV replication was monitored by p24 capture Enzyme-linked immunosorbent assay (ELISA). The single round infection [with green fluorescent protein (GFP) reporter MLV and HIV], virucidal and time-of-additions (HSV) assays were utilized to determine the mode of anti-viral activity. The toxicity of IMOD for cells was monitored by XTT (sodium 3_-[1 (phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid) cell proliferation assay kit. RESULTS: IMOD inhibited 50% of HIV-1 and HSV replication (IC(50)) at 6.5 × 10(-4) and 4.3 × 10(-3)V/V concentrations, respectively. The IC(50) value against HIV-1 and MLV infection were 6 × 10(-4)V/V and 4.9 × 10(-4)V/V. Virucidal assay showed that IMOD reduces the potency of HIV and HSV particles to 41 and 54% of control, respectively. Time-of-addition study revealed that IMOD inhibits the replication of HSV at a stage after penetration of virions to the target cells. CONCLUSIONS: Data from this study indicate that IMOD has significant anti-viral activity against HIV, HSV and MLV. Setarud could be subjected to further investigation after isolation of the constituents and determination of the toxic components. |
format | Online Article Text |
id | pubmed-3469945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-34699452012-10-19 The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials Zabihollahi, Rezvan Namazi, Rahele Aghasadeghi, Mohammad Reze Esfahani, Azar Farhang Sadat, Seyed Mehdi Modarressi, Mohammad Hossein Indian J Pharmacol Research Article OBJECTIVES: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has been proved in previous clinical trials. Here the in vitro inhibitory effect of IMOD against HIV-1, Herpes simplex virus (HSV) and murine leukemia viruses (MLV) was evaluated. MATERIALS AND METHODS: HIV single cycle replication and HSV plaque reduction assays were used to evaluate the anti-viral effect. The level of HIV replication was monitored by p24 capture Enzyme-linked immunosorbent assay (ELISA). The single round infection [with green fluorescent protein (GFP) reporter MLV and HIV], virucidal and time-of-additions (HSV) assays were utilized to determine the mode of anti-viral activity. The toxicity of IMOD for cells was monitored by XTT (sodium 3_-[1 (phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid) cell proliferation assay kit. RESULTS: IMOD inhibited 50% of HIV-1 and HSV replication (IC(50)) at 6.5 × 10(-4) and 4.3 × 10(-3)V/V concentrations, respectively. The IC(50) value against HIV-1 and MLV infection were 6 × 10(-4)V/V and 4.9 × 10(-4)V/V. Virucidal assay showed that IMOD reduces the potency of HIV and HSV particles to 41 and 54% of control, respectively. Time-of-addition study revealed that IMOD inhibits the replication of HSV at a stage after penetration of virions to the target cells. CONCLUSIONS: Data from this study indicate that IMOD has significant anti-viral activity against HIV, HSV and MLV. Setarud could be subjected to further investigation after isolation of the constituents and determination of the toxic components. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3469945/ /pubmed/23087503 http://dx.doi.org/10.4103/0253-7613.99301 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zabihollahi, Rezvan Namazi, Rahele Aghasadeghi, Mohammad Reze Esfahani, Azar Farhang Sadat, Seyed Mehdi Modarressi, Mohammad Hossein The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title | The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title_full | The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title_fullStr | The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title_full_unstemmed | The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title_short | The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
title_sort | in vitro anti-viral potential of setarud (imod™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469945/ https://www.ncbi.nlm.nih.gov/pubmed/23087503 http://dx.doi.org/10.4103/0253-7613.99301 |
work_keys_str_mv | AT zabihollahirezvan theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT namazirahele theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT aghasadeghimohammadreze theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT esfahaniazarfarhang theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT sadatseyedmehdi theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT modarressimohammadhossein theinvitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT zabihollahirezvan invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT namazirahele invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT aghasadeghimohammadreze invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT esfahaniazarfarhang invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT sadatseyedmehdi invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials AT modarressimohammadhossein invitroantiviralpotentialofsetarudimodacommercialherbalmedicinewithprotectiveactivityagainstacquiredimmunedeficiencysyndromeinclinicaltrials |